Despite the fact that less than 10% of ER-positive, HER2-negative, low-burden axillary disease, early invasive breast cancers benefit from chemotherapy [7], the utilization of adjuvant chemotherapy in the management of ER-positive early breast cancer has resulted in the reduction of breast cancer-related mortality [8]. The gene discussed is ERBB2; the disease is breast cancer.